BiotechTube

Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 16/100
16
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Vascular System Injuries

Conditions

Vascular System Injuries

Trial Timeline

— → —

NCT ID
NCT03631056

About Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV)

Acellular Tissue Engineered Vessel (ATEV) / Human Acellular Vessel (HAV) is a pre-clinical stage product being developed by Humacyte for Vascular System Injuries. The current trial status is completed. This product is registered under clinical trial identifier NCT03631056. Target conditions include Vascular System Injuries.

What happened to similar drugs?

20 of 20 similar drugs in Vascular System Injuries were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅donepezil hydrochloride (Aricept)EisaiApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03631056Pre-clinicalCompleted

Competing Products

20 competing products in Vascular System Injuries

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
olmesartanDaiichi SankyoPre-clinical
26
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
LexiscanAstellas PharmaPhase 2
35
YM872 (zonampanel)Astellas PharmaPhase 2
35